MedTrace Logo

Safety and Efficacy Evaluation of IM19 CAR-T Cells

NCT03142646 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-05-01

No results posted yet for this study

Summary

Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia or CD19+ B-all.

Conditions

Interventions

BIOLOGICAL

IM19 CAR-T

All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.

Sponsors & Collaborators

  • Beijing Immunochina Medical Science & Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • hui liu, MD · Beijing Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-30
Primary Completion
2018-06-01
Completion
2018-10-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03142646 on ClinicalTrials.gov